Tags Archive Navigation
icon
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)
-
Media ReleaseNew data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
-
Media ReleaseNovartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
-
Media ReleaseNovartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz
-
Media ReleaseNovartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an
-
Media ReleaseNovartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
-
Media ReleaseGlobal Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline
-
Media ReleasePositive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine
-
Media ReleaseNovartis announces NEJM publication of positive Phase III REACH3 data for Jakavi in chronic GvHD
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 31
- › Next page